The WHO's prequalification of Artemether-lumefantrine is a landmark decision, as it is the first antimalarial treatment designed for the youngest victims of malaria, which has historically posed a significant threat to children. In 2024, there were an estimated 282 million malaria cases and 610,000 deaths globally, with children under five accounting for three-quarters of those fatalities. WHO chief Tedros Adhanom Ghebreyesus emphasized the importance of this development, stating, 'For centuries, malaria has stolen children from their parents... But today, the story is changing.' This approval not only meets international standards of quality, safety, and efficacy but also represents a crucial step towards combating malaria, particularly in Africa, where 95 percent of cases and deaths occur.
HEALTHPublished 25 Apr 2026 • Published 4h ago
Pakistan Vaccination Drive Reaches 18.3 Million Children Worldwide
67% POSITIVE

The World Health Organization (WHO) has approved the first malaria treatment specifically for newborns and infants, Artemether-lumefantrine, marking a significant advancement in pediatric care. This new formulation aims to reduce the risks associated with treating infants with adult medications, potentially saving countless young lives.
Detailed Analysis
SOURCES
3 outlets · 3 articles
